Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Cancer chemotherapy and pharmacology

Results: 1-25/1592

Authors: Song, JM Melera, PW
Citation: Jm. Song et Pw. Melera, Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis, CANC CHEMOT, 48(5), 2001, pp. 339-346

Authors: Bunnell, CA Supko, JG Eder, JP Clark, JW Lynch, TJ Kufe, DW Shulman, LN
Citation: Ca. Bunnell et al., Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patientswith refractory solid malignancies, CANC CHEMOT, 48(5), 2001, pp. 347-355

Authors: Mukohara, T Takeda, K Miyazaki, M Takifuji, N Terakawa, K Negoro, S
Citation: T. Mukohara et al., Japanese experience with second-line chemotherapy with low-dose (60 mg/m(2)) docetaxel in patients with advanced non-small-cell lung cancer, CANC CHEMOT, 48(5), 2001, pp. 356-360

Authors: Bos, AME de Vries, EGE Dombernovsky, P Aamdal, S Uges, DRA Schrijvers, D Wanders, J Roelvink, MWJ Hanauske, AR Bortini, S Capriati, A Crea, AEG Vermorken, JB
Citation: Ame. Bos et al., Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours, CANC CHEMOT, 48(5), 2001, pp. 361-369

Authors: Makino, M Shoji, H Takemoto, D Honboh, T Nakamura, S Kurayoshi, K Kaibara, N
Citation: M. Makino et al., Comparative study between daily and 5-days-a-week administration of oral 5-fluorouracil chemotherapy in mice: determining the superior regimen, CANC CHEMOT, 48(5), 2001, pp. 370-374

Authors: Stecklair, KP Hamburger, DR Egorin, MJ Parise, RA Covey, JM Eiseman, JL
Citation: Kp. Stecklair et al., Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats, CANC CHEMOT, 48(5), 2001, pp. 375-382

Authors: DeHaan, RD Yazlovitskaya, EM Persons, DL
Citation: Rd. Dehaan et al., Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase, CANC CHEMOT, 48(5), 2001, pp. 383-388

Authors: Al Safarjalani, ON Zhou, XJ Naguib, FNM Shi, JX Schinazi, RF el Kouni, MH
Citation: On. Al Safarjalani et al., Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio) acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy, CANC CHEMOT, 48(5), 2001, pp. 389-397

Authors: Hector, S Bolanowska-Higdon, W Zdanowicz, J Hitt, S Pendyala, L
Citation: S. Hector et al., In vitro studies on the mechanisms of oxaliplatin resistance, CANC CHEMOT, 48(5), 2001, pp. 398-406

Authors: Klecker, RW Collins, JM
Citation: Rw. Klecker et Jm. Collins, Thymidine phosphorylase as a target for imaging and therapy with thymine analogs, CANC CHEMOT, 48(5), 2001, pp. 407-412

Authors: Friedman, HS Keir, ST Houghton, PJ Lawless, AA Bigner, DD Waters, SJ
Citation: Hs. Friedman et al., Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice, CANC CHEMOT, 48(5), 2001, pp. 413-416

Authors: Konstadoulakis, MM Antonakis, PT Tsiblouis, BG Stathopoulos, GP Manouras, AP Mylonaki, DB Golematis, BX
Citation: Mm. Konstadoulakis et al., A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma, CANC CHEMOT, 48(5), 2001, pp. 417-420

Authors: Pinheiro, JPV Lanvers, C Boos, J
Citation: Jpv. Pinheiro et al., Use of PEG-asparaginase in the treatment of patients with solid tumors, CANC CHEMOT, 48(5), 2001, pp. 421-422

Authors: Murray, R
Citation: R. Murray, Role of anti-aromatase agents in postmenopausal advanced breast cancer, CANC CHEMOT, 48(4), 2001, pp. 259-265

Authors: Thomas, AL O'Byrne, K Furber, L Jeffery, K Steward, WP
Citation: Al. Thomas et al., A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer, CANC CHEMOT, 48(4), 2001, pp. 266-268

Authors: Heath, EI O'Reilly, S Humphrey, R Sundaresan, P Donehower, RC Sartorius, S Kennedy, MJ Armstrong, DK Carducci, MA Sorensen, JM Kumor, K Kennedy, S Grochow, LB
Citation: Ei. Heath et al., Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors, CANC CHEMOT, 48(4), 2001, pp. 269-274

Authors: Warren, KE Patel, MC Aikin, AA Widemann, B Libucha, M Adamson, PC Neuwirth, R Benziger, D O'Toole, T Ford, K Patronas, N Packer, RJ Balis, FM
Citation: Ke. Warren et al., Phase I trial of lobradimil (RMP-7) and carboplatin in children with braintumors, CANC CHEMOT, 48(4), 2001, pp. 275-282

Authors: Yamamoto, S Kurebayashi, J Kurosumi, M Kunisue, H Otsuki, T Tanaka, K Sonoo, H
Citation: S. Yamamoto et al., Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts, CANC CHEMOT, 48(4), 2001, pp. 283-288

Authors: Zavadova, E Savary, CA Templin, S Verschraegen, CF Freedman, RS
Citation: E. Zavadova et al., Maturation of dendritic cells from ovarian cancer patients, CANC CHEMOT, 48(4), 2001, pp. 289-296

Authors: Herman, EH Zhang, J Rifai, N Lipshultz, SE Hasinoff, BB Chadwick, DP Knapton, A Chai, J Ferrans, VJ
Citation: Eh. Herman et al., The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin and mitoxantrone-induced cardiotoxicity, CANC CHEMOT, 48(4), 2001, pp. 297-304

Authors: Otto, AM Schubert, S Netzker, R
Citation: Am. Otto et al., Changes in the expression and binding properties of the estrogen receptor in MCF-7 breast cancer cells during growth inhibition by tamoxifen and cisplatin, CANC CHEMOT, 48(4), 2001, pp. 305-311

Authors: Pandit, B Roy, M Dutta, J Padhi, BK Bhoumik, G Bhattacharyya, NP
Citation: B. Pandit et al., Co-amplification of dhfr and a homologue of hmsh3 in a Chinese hamster methotrexate-resistant cell line correlates with resistance to a range of chemotherapeutic drugs, CANC CHEMOT, 48(4), 2001, pp. 312-318

Authors: Newman, RA Yang, J Finlay, MRV Cabral, F Vourloumis, D Stephens, LC Troncoso, P Wu, XB Logothetis, CJ Nicolaou, KC Navone, NM
Citation: Ra. Newman et al., Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts, CANC CHEMOT, 48(4), 2001, pp. 319-326

Authors: Stater, LM Stupecky, M Sweet, P Osann, K Eklof, A Arquilla, ER
Citation: Lm. Stater et al., Etoposide induction of tumor immunity in Lewis lung cancer, CANC CHEMOT, 48(4), 2001, pp. 327-332

Authors: Moreira, A Lobato, R Morais, J Silva, S Ribeiro, J Figueira, A Vale, D Sousa, C Araujo, F Fernandes, A Oliveira, J Passos-Coelho, JL
Citation: A. Moreira et al., Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer, CANC CHEMOT, 48(4), 2001, pp. 333-337
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>